SUBSCRIBE
SUBSCRIBE

Montana

PRESS RELEASES
Press Releases
Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System
September 23, 2024
 · 
6 min read
Press Releases
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
September 18, 2024
 · 
5 min read
Press Releases
Xtant Medical Announces $5.0 Million Private Placement
August 8, 2024
 · 
5 min read
Press Releases
Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024
August 8, 2024
 · 
1 min read
Press Releases
Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
August 8, 2024
 · 
14 min read
Press Releases
America’s Leading Online Chronic Care Management Educational Program: Hyalite Care Academy
August 2, 2024
 · 
3 min read
Press Releases
Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis
July 30, 2024
 · 
2 min read
Press Releases
Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
July 25, 2024
 · 
1 min read
Press Releases
INIMMUNE ANNOUNCES FIRST CANCER PATIENT DOSED IN PHASE 1 CLINICAL STUDY USING THE IMMUNOTHERAPEUTIC INI-4001, A NOVEL TLR7/8 AGONIST
July 24, 2024
 · 
2 min read
Xtant Medical to Participate in 21st Annual Craig-Hallum Institutional Investor Conference on May 29
May 22, 2024
 · 
1 min read
Business
Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
May 15, 2024
 · 
13 min read
Drug Development
INIMMUNE ANNOUNCES SUCCESSFUL PHASE 1 CLINICAL RESULTS FOR DISEASE MODIFYING ALLERGY TREATMENT, INI-2004
May 15, 2024
 · 
3 min read
Microbion Receives Award at Advanced Wound Care Summit USA’s Innovation Showcase
April 25, 2024
 · 
4 min read
Microbion Selected to Present at Advanced Wound Care Summit USA
April 15, 2024
 · 
3 min read
Drug Development
Microbion’s Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal
April 4, 2024
 · 
6 min read
FDA
Microbion’s Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections
January 30, 2024
 · 
4 min read
Business
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
January 8, 2024
 · 
4 min read
Business
FYR Diagnostics Welcomes Dr. Kirk Tanner and Dr. Andy Hill to its Scientific Advisory Board
November 28, 2023
 · 
3 min read
BioForest
Alercell’s Latest Intellectual Property In-License Bolsters Leukemia Diagnostic Test Advancements
October 25, 2023
 · 
2 min read
BioForest
Inimmune Collaborates with Boston Children’S Hospital to Develop Novel Adjuvants
October 24, 2023
 · 
3 min read
Load More